Monday - July 15, 2024
Tucatinib Plus Trastuzumab Emtansine May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
December 08, 2023
SAN ANTONIO, Texas, Dec. 8 (TNSres) -- The American Association for Cancer Research posted the following news release:

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium, held . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

What's your
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products